Ken Griffin Aclaris Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 13,200 shares of ACRS stock, worth $32,340. This represents 0.0% of its overall portfolio holdings.

Number of Shares

13,200

Previous 37,500 64.8%

Holding current value

$32,340

Previous $46,000 69.57%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.01 - $1.36 $55,334 - $74,510	-54,787 Reduced 5.89%	875,216 $962,000
Q1 2024 May 15, 2024	SELL	$0.92 - $1.44 $4.1 Million - $6.42 Million	-4,458,786 Reduced 82.74%	930,003 $1.15 Million
Q4 2023 Feb 14, 2024	BUY	$0.64 - $6.49 $1.3 Million - $13.2 Million	2,031,549 Added 60.51%	5,388,789 $5.66 Million
Q3 2023 Nov 14, 2023	BUY	$6.56 - $10.95 $4.88 Million - $8.15 Million	744,166 Added 28.48%	3,357,240 $23 Million
Q2 2023 Aug 14, 2023	SELL	$7.89 - $10.64 $3.9 Million - $5.26 Million	-494,690 Reduced 15.92%	2,613,074 $27.1 Million
Q1 2023 May 15, 2023	BUY	$7.07 - $17.95 $14.4 Million - $36.5 Million	2,032,724 Added 189.08%	3,107,764 $25.1 Million
Q4 2022 Feb 14, 2023	SELL	$14.33 - $18.37 $621,592 - $796,835	-43,377 Reduced 3.88%	1,075,040 $16.9 Million
Q3 2022 Nov 14, 2022	BUY	$13.07 - $18.22 $2.16 Million - $3.01 Million	165,345 Added 17.35%	1,118,417 $17.6 Million
Q2 2022 Aug 15, 2022	SELL	$10.16 - $17.08 $194,340 - $326,706	-19,128 Reduced 1.97%	953,072 $13.3 Million
Q1 2022 May 16, 2022	SELL	$9.74 - $17.92 $385,431 - $709,130	-39,572 Reduced 3.91%	972,200 $16.8 Million
Q4 2021 Feb 14, 2022	SELL	$12.27 - $18.49 $636,138 - $958,614	-51,845 Reduced 4.87%	1,011,772 $14.7 Million
Q3 2021 Nov 15, 2021	SELL	$13.38 - $18.8 $2.19 Million - $3.08 Million	-163,776 Reduced 13.34%	1,063,617 $19.1 Million
Q2 2021 Aug 16, 2021	SELL	$17.08 - $29.6 $1.71 Million - $2.96 Million	-99,956 Reduced 7.53%	1,227,393 $21.6 Million
Q1 2021 May 17, 2021	BUY	$5.86 - $27.73 $7.54 Million - $35.7 Million	1,286,007 Added 3110.66%	1,327,349 $33.4 Million
Q4 2020 Feb 16, 2021	BUY	$2.65 - $7.61 $43,030 - $123,571	16,238 Added 64.68%	41,342 $267,000
Q3 2020 Nov 16, 2020	BUY	$1.5 - $2.71 $37,656 - $68,031	25,104 New	25,104 $65,000
Q2 2020 Aug 14, 2020	SELL	$1.04 - $1.73 $53,300 - $88,662	-51,250 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$0.75 - $2.18 $18,359 - $53,364	24,479 Added 91.44%	51,250 $53,000
Q4 2019 Feb 14, 2020	SELL	$1.02 - $1.97 $48,922 - $94,487	-47,963 Reduced 64.18%	26,771 $51,000
Q3 2019 Nov 14, 2019	BUY	$0.79 - $2.47 $33,401 - $104,434	42,281 Added 130.28%	74,734 $80,000
Q2 2019 Aug 14, 2019	SELL	$2.13 - $7.06 $333,106 - $1.1 Million	-156,388 Reduced 82.81%	32,453 $71,000
Q1 2019 May 15, 2019	SELL	$5.63 - $7.84 $2.06 Million - $2.87 Million	-365,497 Reduced 65.93%	188,841 $0
Q4 2018 Feb 14, 2019	SELL	$6.3 - $15.4 $2.07 Million - $5.05 Million	-328,026 Reduced 37.18%	554,338 $4.1 Million
Q3 2018 Nov 13, 2018	BUY	$14.38 - $20.89 $203,246 - $295,259	14,134 Added 1.63%	882,364 $0
Q2 2018 Aug 10, 2018	SELL	$16.46 - $20.33 $470,871 - $581,580	-28,607 Reduced 3.19%	868,230 $0
Q1 2018 May 11, 2018	BUY	$17.08 - $25.64 $12.8 Million - $19.2 Million	748,422 Added 504.28%	896,837 $15.7 Million
Q4 2017 Feb 09, 2018	SELL	$21.47 - $27.8 $2.01 Million - $2.6 Million	-93,601 Reduced 38.68%	148,415 $3.66 Million
Q3 2017 Nov 09, 2017	BUY	$23.02 - $28.8 $5.57 Million - $6.97 Million	242,016	242,016 $6.25 Million

Others Institutions Holding ACRS

# of Institutions

Shares Held

53.7M

Call Options Held

32.4K

Put Options Held

3.3K

View Full List

About Aclaris Therapeutics, Inc.

Ticker ACRS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 66,671,800
Market Cap $163M
Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...

More about ACRS

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account